



Board of Health Update

Tracie Newman, MD, MPH, FAAP

Health Officer, Fargo Cass Public Health

Monkeypox Update

Monkeypox Cases decreasing

- WHO reports 22% decline in MPV cases globally
- To date, 105 countries have reported 62,000 confirmed cases
- Total of 23 deaths
- In US, CDC reports total of 24,364 monkeypox cases; cases dropping
- In ND, 6 total MPV cases
- Cases still predominantly involve young adult men

Biological risk

Biological safety

Hazard groups (since 1994)

Hazard group	Pathogenicity for humans	Hazard to workers	Spread to the community	Effective prophylaxis or treatment
1	Unlikely to cause human disease	Unlikely	Unlikely	Available
 2	Can cause human disease	Maybe	Unlikely	Usually available
3	Can cause severe human disease	Maybe serious	May spread	Usually available
4	Causes deadly human disease	Serious	Likely	Usually non

Adult healthy worker !!!

Monkeypox

- Many public health agencies downgrading classification of disease (access to vaccines and treatments, broader understanding of spread / community transmission)
- Monkeypox now considered a Hazard Group 3 organism
 - Others in this category include Salmonella Typhi, HIV, hepatitis B and C, and Mycobacterium tuberculosis - diseases all managed in the community

Flu Season



**FLU
SEASON
AHEAD**

Unusually Severe Flu Season Predicted


- Health experts warning of potentially more severe flu season
- Two main reasons:
 - COVID-19 restrictions (masking, etc) have mostly been lifted
 - Lower population immunity due to fewer people getting influenza over the past 2 years
- “Twindemic” of both flu and coronavirus unlikely to occur this year
- Southern Hemisphere countries, where it is currently winter, seeing tough seasons with case rates peaking earlier than usual
 - Australia experiencing worse flu season in 5 years

**** October is a great time to get both the bivalent COVID-19 booster and flu vaccine!***

CDC Reporting Increasing Flu Activity

- Influenza and influenza-like illnesses rising, higher than normal this time of year in Southeast and central parts of U.S.
 - Both adult and pediatric cases
- During typical influenza seasons, cases increase in December; peak in February
- A school district in San Diego reported hundreds of absences due to a flu outbreak
 - Most kids reported cough, sore throat, congestion, fever
- Earlier than expected rise in other viruses also being seen: RSV, rhinovirus, enterovirus
- Everyone ages 6 months and older is recommended to get annual flu vaccine
- Two weeks is needed to establish full protection after a flu vaccine

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 3, 2021 – October 1, 2022



COVID Vaccines



Bivalent COVID-19 Boosters for Kids

- Bivalent boosters (original SARS-CoV-2 strain + BA.4/5) currently available for ages 12 and older
- Oct 12, CDC and FDA granted EUA for both Pfizer and Moderna bivalent boosters in younger children
 - Pfizer for ages 5-11
 - Moderna for ages 6-17
- Pfizer has begun trials down to ages 6 months and Moderna expected to seek EUA for ages 6 months – 6 years by end of year

ND COVID-19 Vaccine Rates



Dashboard Last Updated Friday, 10/14/2022

Data as of Thursday, 10/6/2022

Coverage Rates | **Doses Administered** | Demographics | County Level | Enrolled Providers

COVID-19 Vaccine Coverage Rates Select filters to view time or county specific data.

	At least one dose	Primary series complete	Booster dose	Second booster dose
6 months and older 435,695 ND residents	55.1%			
5 and older 432,617 ND residents	58.8%	54.7% 403,047 ND residents	55.0% 221,852 ND residents	
12 and older 413,687 ND residents	58.8%	63.0% 386,460 ND residents	56.6% 218,566 ND residents	
18 and older 386,890 ND residents	65.0%	60.7% 361,512 ND residents	57.9% 209,495 ND residents	
65 and older 104,241 ND residents	81.4%	77.2% 98,963 ND residents	78.6% 77,812 ND residents	48.2% 37,522 ND residents



Resources

- [Global monkeypox cases drop 22% | CIDRAP \(umn.edu\)](#)
- [Nation warned to brace for a difficult flu season | The Hill](#)
- [Weekly U.S. Influenza Surveillance Report | CDC](#)
- [Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age | Pfizer](#)
- [Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids | Reuters](#)
- [COVID19 Vaccine Dashboard | Department of Health \(nd.gov\)](#)